The estimated Net Worth of David Cragg is at least $10.3 Million dollars as of 9 November 2021. Mr. Cragg owns over 45,000 units of Cytokinetics Inc stock worth over $8,559,377 and over the last 20 years he sold CYTK stock worth over $720,393. In addition, he makes $1,051,810 as Chief Human Resource Officer und Chief Administrative Officer at Cytokinetics Inc.
Sign up
Mr. Cragg CYTK stock SEC Form 4 insiders trading
David has made over 8 trades of the Cytokinetics Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 45,000 units of CYTK stock worth $434,250 on 9 November 2021.
The largest trade he's ever made was exercising 45,000 units of Cytokinetics Inc stock on 9 November 2021 worth over $434,250. On average, David trades about 3,223 units every 8 days since 2005. As of 9 November 2021 he still owns at least 159,185 units of Cytokinetics Inc stock.
You can see the complete history of Mr. Cragg stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
David Cragg biography
David W. Cragg is Chief Human Resource Officer, Chief Administrative Officer of the Company. Mr. Cragg has served as our Chief Human Resources and Administration Officer since February 2019. Mr. Cragg served as our Senior Vice President, Human Resources from July 2009 through February 2019 and as our Vice President of Human Resources from February 2005 through June 2009. From October 2000 until January 2005, Mr. Cragg managed his own human resources consulting practice. From March 2000 until its acquisition in September 2000 by Yahoo!, Inc., he was Vice President, Human Resources for eGroups Inc., an internet email management company. Prior to October 2000, Mr. Cragg was a Principal Human Resources Consultant at Genentech, Inc. Mr. Cragg received a B.A. in Industrial Psychology from the University of California, Santa Cruz.
What is the salary of David Cragg?
As the Chief Human Resource Officer und Chief Administrative Officer of Cytokinetics Inc, the total compensation of David Cragg at Cytokinetics Inc is $1,051,810. There are 4 executives at Cytokinetics Inc getting paid more, with Robert Blum having the highest compensation of $3,475,980.
How old is David Cragg?
David Cragg is 64, he's been the Chief Human Resource Officer und Chief Administrative Officer of Cytokinetics Inc since 2019. There are 9 older and 11 younger executives at Cytokinetics Inc. The oldest executive at Cytokinetics Inc is Dr. James A. Spudich Ph.D., 79, who is the Co-Founder & Member of Scientific Advisory Board.
What's David Cragg's mailing address?
David's mailing address filed with the SEC is 350, Oyster Point Boulevard, South San Francisco, San Mateo County, California, 94080, United States.
Insiders trading at Cytokinetics Inc
Over the last 21 years, insiders at Cytokinetics Inc have traded over $50,353,277 worth of Cytokinetics Inc stock and bought 879,922 units worth $7,454,506 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Capital Ltd Portfolio Servi... und Partners L P/Ilbiotechnolog.... On average, Cytokinetics Inc executives and independent directors trade stock every 14 days with the average trade being worth of $1,225,580. The most recent stock trade was executed by B Lynne Parshall on 9 September 2024, trading 5,000 units of CYTK stock currently worth $108,050.
What does Cytokinetics Inc do?
cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. as a leader in muscle biology and the mechanics of muscle performance, we're developing small molecule drug candidates specifically engineered to increase muscle function and contractility.
What does Cytokinetics Inc's logo look like?
Complete history of Mr. Cragg stock trades at Cytokinetics Inc
Cytokinetics Inc executives and stock owners
Cytokinetics Inc executives and other stock owners filed with the SEC include:
-
Robert Blum,
President, Chief Executive Officer, Director -
Fady Malik,
Executive Vice President - Research and Development -
Mark Schlossberg,
Senior Vice President, General Counsel, Secretary -
Ching Jaw,
Chief Financial Officer, Senior Vice President -
David Cragg,
Chief Human Resource Officer, Chief Administrative Officer -
Robert I. Blum,
CEO, Pres & Director -
Dr. Fady Ibraham Malik,
Exec. VP of R&D -
Mark A. Schlossberg,
Sr. VP of Legal, Gen. Counsel & Sec. -
Ching W. Jaw,
Sr. VP & CFO -
David W. Cragg,
Chief HR & Admin. Officer -
Leonard Patrick Gage,
Independent Chairman of the Board -
Wendall Wierenga,
Independent Director -
B. Lynne Parshall,
Independent Director -
John Henderson,
Independent Director -
Santo Costa,
Independent Director -
Sandford Smith,
Independent Director -
Edward Kaye,
Independent Director -
Robert Califf,
Independent Director -
Nancy Wysenski,
Independent Director -
Diane Weiser,
IR Contact Officer -
Robert Wong,
Chief Accounting Officer, Vice President -
Kari K. Loeser J.D.,
VP & Chief Compliance Officer -
Robert Wong,
VP & Chief Accounting Officer -
Jeff Lotz,
VP of Sales & Operations -
Dr. James A. Spudich Ph.D.,
Co-Founder & Member of Scientific Advisory Board -
Bradley Paul Morgan,
SVP Drug Discovery & Early Dev -
Caryn Gordon Mc Dowell,
GC & Chief Compliance Officer -
Elisabeth Schnieders,
Sr. VP, Business Development -
L Patrick Gage,
Director -
Bonnie Charpentier,
SVP Regulatory & Compliance -
Robert Arthur Harrington,
Director -
Associates Vi Lp Srb,
10% owner -
Sung Lee,
EVP, Chief Financial Officer -
Peter S Roddy,
SVP Finance & CAO -
Muna Bhanji,
Director -
Michael Rabson,
SVP Business Dev/Legal & GC -
A Grant Iii Heidrich,
Director -
Mark Mcdade,
Director -
Brett A Pletcher,
EVP, Chief Legal Officer -
Sharon Barbari,
Sr. VP, Finance & CFO -
Charles J Homcy,
Director -
James H Sabry,
President and CEO -
David J Jr Morgans,
SVP-Drug Discovery and Dev -
James A Spudich,
Director -
Michael Schmertzler,
Director -
Jay K Trautman,
VP, Technology -
Stephen M Dow,
Director -
Denise Gilbert,
Director -
Capital Ltd Portfolio Servi...,
-
Suisse First Boston/Credit ...,
-
John Vdomenik Stephen Lbayl...,
-
William J Rutter,
Director -
Ixmayfield Ix Management Ll...,
-
Rosen Vii Affiliates Fund L...,
10% owner -
Associates Vii Lp Srb,
10% owner -
Associates Viii Lp Srb,
10% owner -
Rosen Viii Affiliates Fund ...,
10% owner -
Rosen Fund Viii Lp Sevin,
10% owner -
Rosen Fund Vi Lp Sevin,
10% owner -
Rosen Fund Vii Lp Sevin,
10% owner -
Rosen Vi Affiliates Fund Lp...,
10% owner -
Partners L P/Ilbiotechnolog...,
-
Partners L P/Ilbiotechnolog...,
-
Andrew Callos,
EVP, Chief Commercial Officer